Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Optimizing Patient-Centered Care for Relapsed/Refractory CLL With the Latest Evidence and Guidance Updates: Precision Education with Real-World Insights

Clinical Thought

Experts answer your questions related to the program, “Optimizing Patient-Centered Care for Relapsed/Refractory CLL With the Latest Evidence and Guidance Updates: Precision Education with Real-World Insights”. This social media forum provides you with ongoing access to experts for your questions and challenging cases throughout the certified life of this program.

Released: April 21, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the CLL Society

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

CLL Society

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of community hematologists/oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who are part of the multidisciplinary care team for people with R/R CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment sequences leveraging novel targeted and/or cellular therapies for eligible patients with R/R CLL to optimize clinical benefit and quality of life in alignment with patient preferences, clinical evidence, and current guidelines

  • Employ guideline- and expert-recommended biomarker testing to assess patients with R/R CLL for acquired resistance mutations to guide therapy selection and optimal sequencing

  • Assess emerging clinical evidence for novel targeted and cellular therapies and the clinical implications for management of R/R CLL

  • Apply shared decision-making and communication strategies to support patient quality of life and engagement in care for R/R CLL

Disclosure

Primary Author

Nitin Jain, MD: researcher: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, Ascentage, AstraZeneca, BeOne, Bioheng, Bristol Myers Squibb, Carna, Cellectis, Fate, Genentech, Kisoji, Kite/Gilead, Lilly, Mingsight, Newave, Novartis, Pharmacyclics, Precision Biosciences, Sana Biotechnology, Takeda, Triarm, Ubix; consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, AstraZeneca, Autolus, BeOne, Bristol Myers Squibb, Cellectis, Genentech, Janssen, Kite/Gilead, Lilly, Novalgen, Nurix, Pharmacyclics, SERB.

Jennifer Woyach, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Genentech, Johnson & Johnson, Loxo/Lilly, Merck, Newave, Schrödinger.